Hepatitis C virus (HCV) infection is one of the important causes of chronic liver diseases, including hepatic fibrosis, liver cirrhosis and hepatocellular carcinoma. The goals of hepatitis C treatment are to eradicate HCV and to prevent related hepatic complications, manifestations of HCV infection and death. A sustained virological response (SVR) is defined as undetectable serum HCV RNA by a sensitive assay at 12 or 24 weeks after treatment completion. The infection is cured in nearly 100% of patients who achieve an SVR. Newly introduced direct-acting antivirals act at a specific step of the viral life cycle and enable an SVR of over 90%. There are a number of unmet needs in HCV therapies that should be addressed, and are anticipated to be resolved in the near future. 
Modified from [3] . KASL, Korean Association for the Study of the Liver; HCV, hepatitis C virus; OPr＋D, ombitasvir/paritaprevir/ritonavir＋dasabuvir; R, weight-based ribavirin; PR, pegylated interferon + ribavirin. Modified from [3] . KASL, Korean Association for the Study of the Liver; R*, ribavirin started from 600 mg/d; R, weight-based ribavirin. Modified from [3] . KASL, Korean Association for the Study of the Liver; HCV, hepatitis C virus; R, weight-based ribavirin; PR, pegylated interferon + ribavirin. 중심 단어: C형간염; 만성; 치료
